51st week of 2013 patent applcation highlights part 39 |
Patent application number | Title | Published |
20130336891 | FORMULATION OF ACOUSTICALLY ACTIVATABLE PARTICLES HAVING LOW VAPORIZATION ENERGY AND METHODS FOR USING SAME - Formulation of acoustically activatable particles having low vaporization energy and methods for using same are disclosed. According to one aspect, a method of producing particles of materials includes, with a first substance that includes at least one component that is a gas at room temperature and atmospheric pressure, performing one of: causing the first substance to condense to a liquid phase, and extruding or emulsifying the first substance into or in the presence of a second substance to create a droplet or emulsion in which the first substance is encapsulated by the second substance; or extruding or emulsifying the first substance into or in the presence of a second substance to create a bubble in which the first substance is encapsulated by the second substance and wherein at least some of the first substance is in a gaseous phase, and causing the first substance to condense to a liquid phase, which causes the bubble to transform into a droplet or emulsion. The droplet or emulsion so created is an activatable phase change agent that is stable at room temperature and pressure. | 2013-12-19 |
20130336892 | CHIMERIC T1R TASTE RECEPTOR POLYPEPTIDES AND NUCLEIC ACID SEQUENCES ENCODING AND CELL LINES THAT EXPRESS SAID CHIMERIC T1R POLYPEPTIDES - The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or sub-units thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli. Further, the invention relates to the constitutive of cell lines that stably or transiently co-express a combination of T1R1 and T1R3; or T1R2 and T1R3; under constitutive or inducible conditions. The use of these cells lines in cell-based assays to identify umami and sweet taste modulatory compounds is also provided, particularly high throughput screening assays that detect receptor activity by use of fluorometric imaging. | 2013-12-19 |
20130336893 | Exedin-4 Peptide Analogues - The present invention relates to exendin-4 peptide analogues and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. | 2013-12-19 |
20130336894 | ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR ANTIBODIES FOR DIAGNOSTIC AND CLINICAL APPLICATIONS - The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases. | 2013-12-19 |
20130336895 | FOLATE TARGETED ENHANCED TUMOR AND FOLATE RECEPTOR POSITIVE TISSUE OPTICAL IMAGING TECHNOLOGY - A method of differentiating tumors from healthy cells in tissue is disclosed. The method includes the steps of providing a marker-folate conjugate, placing the marker-folate conjugate in contact with the tissue and viewing the tissue. | 2013-12-19 |
20130336896 | SWITCHING-TYPE FLUORESCENT NANOPARTICLE PROBE, AND FLUORESCENT MOLECULAR IMAGING METHOD USING SAME - [Problem] To provide a novel fluorescent nanoparticle imaging probe having a switching function (a function to quench a fluorescent dye in a blood component and emit fluorescence in a tumor or an inflamed site to be imaged). | 2013-12-19 |
20130336897 | THERANOSIS OF MACROPHAGE-ASSOCIATED DISEASES WITH ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES (USPIO) - Macrophages sequester and aggregate ultrasmall superparamagnetic iron oxide nanoparticles (USPIO) in their lysosomes. The amount of USPIO loading of macrophages depends upon the route and dose of administration, and the pharmacokinetics of accumulation and removal. Both fixed macrophages and activated macrophages associated with inflammatory diseases and cancer phagocytize USPIOs, and the loaded macrophages can serve to identify the extent of a macrophage-dependent disease as well as to direct treatment options. Furthermore, the absorption of energy from incident electromagnetic waves by the aggregated nanoparticles can be used for conformal thermotherapy. The USPIOs can further be used to carry drugs to the same activated macrophages. The co-administered drugs can be bound to the USPIO by condition-dependent releasing links that are responsive to local pH or heating. | 2013-12-19 |
20130336898 | PROCESS FOR PREPARING A PHARMACEUTICAL FORMULATION OF CONTRAST AGENTS - The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount offree macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, DO3A, BT-DO3A, HP-DO3A and PCTA, and is preferably DOTA, the said process comprising the following successive steps: b) preparation of a liquid pharmaceutical composition containing, firstly, the complex of macrocyclic chelate with a lanthanide, and, secondly, free macrocyclic chelate and/or free lanthanide; c) measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate C | 2013-12-19 |
20130336899 | ANTIMICROBIAL FORMULATIONS THAT AID IN WOUND HEALING - The invention discloses compositions and formulations for the treatment of clean or infected wounds, some of the inventive formulations can be used to reduce or eliminate microbial contamination from surfaces such as skin, and inanimate objects such as countertops, cooking utensils, medical devices, cookware, food, grooming aids and agricultural biocides, and the like. Some of these compositions and formulations are well suited for use in wound dressings. Some of the formulation can kill and/or inhibit the growth of pathogenic bacteria, fungi, spores and viruses. The formulations comprise a compound such as an osmoticum in high enough concentration to create an osmotic gradient and at least one compound that acts to comprise the integrity of a microorganism's membrane or cell wall. These formulations may optimally include at least one agent that thickens the formulations. In some aspects the formulation is in the form of an emulsion. | 2013-12-19 |
20130336900 | VOC-Free Compressed Gas Aerosol Compositions - Certain surfactants suitable for use alone to dissolve a water-insoluble component in compositions is described for providing VOC-free compressed gas aerosol compositions. The compositions include water-insoluble component(s), a surfactant and water. The water-insoluble component(s) can be active agent(s), such as fragrance(s) and/or an insecticide(s). The surfactant is present as a single surfactant which, in the absence of a solvent, dissolves or disperses the water-insoluble component(s) and provides a homogenous blend in water which provides a stable compressed gas emulsion. The surfactant is an anionic surfactant or a nonionic surfactant, in particular nonionic alkylpolyglycosides; nonionic cocoglucoside; nonionic alkylene oxide extended chain alkylpolyglycosides; anionic sodium lauryl ether sulfate (SLES), nonionic C | 2013-12-19 |
20130336901 | FLAVORANT ESTER SALTS OF POLYCARBOXYLIC ACIDS AND METHODS FOR IMMOBILIZING AND DELIVERING FLAVORANTS CONTAINING HYDROXYL GROUPS - Compositions are provided which contain immobilized flavorants for flavor delivery. In particular, smoking compositions are provided which contain flavorant ester salts of polycarboxylic acids. | 2013-12-19 |
20130336902 | Personal Care Compositions Comprising a Di-Amido Gellant and Methods of Using - A personal care composition is disclosed comprising a di-amido gellant, wherein the di-amido gellant has a formula: | 2013-12-19 |
20130336903 | Personal Care Compositions Comprising a pH Tuneable Gellant and Methods of Using - A personal care composition is disclosed comprising a pH tuneable gellant. The pH tuneable gellant has a formula of: | 2013-12-19 |
20130336904 | NOVEL ANTI-AGEING PEPTIDES MODULATING SURVIVIN AND COMPOSITIONS INCLUDING SAME - The present invention relates to peptide compounds of the general formula (I) R | 2013-12-19 |
20130336905 | COMPOSITIONS OF ENHANCED VISCOSITY, CLARITY, OR BOTH ENHANCED VISCOSITY AND CLARITY - Provided herein are compositions that exhibit enhanced clarity, higher viscosity, or both enhanced clarity and higher viscosity for a wide range of application arts, such as personal care compositions. The compositions have lightly- to moderately-crosslinked PVP and at least one additive. | 2013-12-19 |
20130336906 | METHOD OF IMPROVING THE APPEARANCE OF AGING SKIN - A method of improving the appearance of aging skin that includes applying an effective amount of artichoke leaf extract and carob fruit extract in combination to a target area of skin that exhibits a sign of aging skin. The composition is applied for a period of time sufficient to improve the appearance of the aging skin. | 2013-12-19 |
20130336907 | HIGH VISCOSITY HEAT-TREATED XANTHAN GUM - The present invention is directed to heat treated xanthan gums, which have improved solution viscosity over other xanthan gums heat-treated under the same processing conditions while maintaining the improved ease of use and the short, non-stringy gel texture of heat treated xanthan gums. Such high solution viscosity xanthan gums are suitable in a variety of applications, including cosmetic and personal care compositions. | 2013-12-19 |
20130336908 | SUNSCREEN COSMETIC COMPOSITION - Provided is a sunscreen cosmetic composition that effectively protects from both UVA and UVB, has moist and cool feeling on use as well as excellent stability, and is able to form a film having a good ultraviolet protection effect when applied to skin. An oil-in-water sunscreen cosmetic composition comprising: (a) an aqueous dispersion of an oil-soluble ultraviolet absorbent; (b) one or two or more of crosslinked polyether-modified silicones and crosslinked alkyl polyether-modified silicones; (c) a low-viscosity silicone oil; and (d) water. The aqueous dispersion of the oil-soluble ultraviolet absorbent is preferably an aqueous dispersion of composite particles of bis-ethylhexyloxyphenol methoxyphenyl triazine and an organic polymer. Furthermore, methylene bisbenzotriazolyl tetramethylbutylphenol is preferably further added. | 2013-12-19 |
20130336909 | PERSONAL CARE AND HEALTH CARE COMPOSITIONS - The present invention relates to health care and personal care compositions comprising a silicone acrylate hybrid composition and at least one health care and/or personal care ingredient. Such compositions tend to provide desirable characteristics for the care and conditioning of hair and skin. | 2013-12-19 |
20130336910 | OLFACTORY RECEPTORS INVOLVED IN THE PERCEPTION OF SWEAT CARBOXYLIC ACIDS AND THE USE THEREOF - The invention relates to the identification of carboxylic acids, present in human sweat, as natural ligands of a specific subgroup of seven olfactory receptor (OR) belonging to class 1 within the OR classification. The invention encompasses the use of the interaction of OR polypeptides and carboxylic acids as the basis of screening assays for agents that specifically modulate the activity of the seven ORs of the invention. | 2013-12-19 |
20130336911 | MOC Compositions - A Malodour counteracting composition, in particular a deodorant composition, comprising at least 25% w/w in total of at least 3 compounds drawn from Group A and Group B following:
| 2013-12-19 |
20130336912 | ANTIPERSPIRANT/DEODORANT COMPOSITIONS - Disclosed are new and improved antiperspirant/deodorant compositions and methods of reducing perspiration, where the new and improved antiperspirant/deodorant compositions contain a water dispersible organic polymer and can reduce the concentration of active antiperspirant ingredients while maintaining antiperspirant efficacy. | 2013-12-19 |
20130336913 | HAIR CARE COMPOSITIONS AND METHODS OF TREATING HAIR - The present invention provides compositions, kits and methods for treating scalp hair. The compositions include fluorinated (but not perfluorinated), non-polymeric compounds in a suitable excipient to provide beneficial effects on hair. | 2013-12-19 |
20130336914 | MALODOR CONTROL COMPOSITIONS HAVING ACTIVATED ALKENES AND METHODS THEREOF - A malodor control composition having activated alkenes and methods thereof are provided. In some embodiments, a catalyst is provided in the composition. The composition is suitable for a variety of applications, including use in fabric and air freshening products. | 2013-12-19 |
20130336915 | PARTICULATE CONSTRUCTS FOR RELEASE OF ACTIVE AGENTS - Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments. | 2013-12-19 |
20130336916 | BOTANICAL INSECTICIDES - The invention generally relates to environmental friendly pesticide compounds, formulations, methods of preparation and application and utilities thereof. More particularly, the invention relates to pesticide compounds and formulations that include terpenes or terpenoids having chemical formula of (C | 2013-12-19 |
20130336917 | POLYMERIC TREATMENT COMPOSITIONS - Compositions are described comprising a polymer; a non-physiological pH solution; and a visualization agent; wherein the polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use. | 2013-12-19 |
20130336918 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT - Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): | 2013-12-19 |
20130336919 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT - Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): | 2013-12-19 |
20130336920 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT - Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): | 2013-12-19 |
20130336921 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT - Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): | 2013-12-19 |
20130336922 | HLA-BINDING PEPTIDES DERIVED FROM PROSTATE-ASSOCIATED ANTIGENIC MOLECULES AND METHODS OF USE THEREOF - Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. More specifically methods of treating patients with prostate cancer comprising administering compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants, are disclosed. | 2013-12-19 |
20130336923 | Carbonic Anhydrase IX (G250) Antibodies and Methods of Use Thereof - The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby. | 2013-12-19 |
20130336924 | Ligands Modified by Circular Permutation as Agonists and Antagonists - The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof. | 2013-12-19 |
20130336925 | Fusion Polypeptides Comprising Mucin-Domain Polypeptide Linkers - The invention provides fusion proteins having improved bioactivity comprising a first polypeptide fusion partner and a second polypeptide fusion partner wherein the first fusion partner is linked to the second fusion partner by a mucin-domain polypeptide linker and wherein the bioactivity of the fusion protein of the invention is improved as compared to fusion of the first polypeptide fusion partner and the second polypeptide fusion partner in the absence of the mucin-domain polypeptide linker. Mucin-domain polypeptide linkers comprise a mucin domain that is rich in potential glycosylation sites, and has a high content of serine and/or threonine and proline, which can represent greater than 40% of the amino acids within the mucin domain and further comprise at least about 60% of its mass due to the glycans. | 2013-12-19 |
20130336926 | IL-1 FAMILY VARIANTS - The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins. | 2013-12-19 |
20130336927 | CULTURING CIRCULAR ssDNA VIRUSES FOR THE PRODUCTION OF VACCINES - The present invention relates to the use of interferon in the in vitro cultivation of animal circular ssDNA virus such as Porcine Circovirus 2 or human TT virus in an animal cell line. Increased titres of animal circular ssDNA virus are obtained by addition of interferons or agents which ensure the production of endogenous interferons by said cell line and/or by the reduction of endosomal-lysosomal system acidification. | 2013-12-19 |
20130336928 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH THERAPEUTIC AGENT(S) IN PATIENTS WITH CONCURRENT NON-CNS CONDITION(S) OR DISORDERS CONTRAINDICATING SYSTEMIC ADMINISTRATION OF THE THERAPEUTIC AGENT(S) - Methods for delivering therapeutic agent(s) to the central nervous system to treat a first CNS-related disease and/or condition while avoiding systemic exposure for patients having a second concurrent non-CNS-related disease and/or condition wherein the presence of the second disease and/or condition contraindicates systemic administration of the therapeutic agent(s) and/or pharmaceutical compound to treat the first disease or condition. The present invention provides these advantages by applying the therapeutic agent(s) and/or pharmaceutical composition(s) to the upper third of the nasal cavity, thereby bypassing the blood-brain barrier and administering the therapeutic agent(s) and/or pharmaceutical compound(s) directly to the CNS. This administration method thus protects the mammalian patient, specifically the second non-CNS-related disease and/or condition, by minimizing systemic exposure to the therapeutic agent(s) and/or pharmaceutical compound(s) administered to treat the first disease and/or condition of the CNS. | 2013-12-19 |
20130336929 | METHODS AND CELLS FOR IDENTIFYING RIG-I PATHWAY REGULATORS - Disclosed herein are methods for identifying compounds for the treatment of viral infection, including RNA viral infection and uses of the compounds as pharmaceutical compositions. The identified compounds modulate the RIG-I pathway in vertebrate cells. | 2013-12-19 |
20130336930 | MYXOMA VIRUS MUTANTS FOR CANCER TREATMENT - Myxoma viruses that are deficient in the activity of a Myxoma virus protein selected from the group consisting of M11L, M063, M 136, M-T4 and M-T7 are useful for treating cancer. | 2013-12-19 |
20130336931 | SYNBIOTIC COMPOSITIONS FOR RESTORATION AND RECONSTITUTION OF GUT MICROBIOTA - The present invention relates to synbiotic compositions comprising probiotic bacterial strains and prebiotic substances that, when combined exhibit synergistic behavior. The synergetic compositions will stimulate the indigenous microflora to restore and reconstitute in vivo gut like conditions after antibiotic associated diarrhea (AAD), and/or other gut infections caused by gastrointestinal pathogens, and relapses thereof, as well as the prevention of said disorders. | 2013-12-19 |
20130336932 | Novel Salmonella Bacteriophage and Uses Thereof - The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of | 2013-12-19 |
20130336933 | 3-DIMENSIONAL SCAFFOLDS FOR IMPROVED DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO HEPATOCYTES - The present invention relates to the use of 3-dimensional (3D) synthetic or animal-derived bioscaffolds as substrates for the improved growth and differentiation of hPS (Human pluripotent stem cells); these scaffolds being adapted for use in conjunction with existing cell culture lab plastic-ware. More specifically, it relates to the seeding of these scaffolds, either alone or in conjunction with various biologic matrix coatings, with hPS cells for the improved differentiation of said hPS cells into hepatocyte or hepatocyte-like cell types. The invention also relates to the seeding of partially-differentiated hepatocyte progenitors onto scaffolds for further differentiation into more mature hepatocyte-cell types. | 2013-12-19 |
20130336934 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided. | 2013-12-19 |
20130336935 | Compositions and Methods for Restoring or Rejuvenating Stem/Progenitor Cell Function - This invention relates to the use of autologous stem/progenitor cells to restore or rejuvenate adult stem cell function in a mammal, wherein the restoration or rejuvenating extends lifespan and/or improves health of the mammal. In addition, the invention also relates to compositions containing one or more regulatory factors secreted or released from isolated mammalian stem/progenitor cells and use of such compositions to extend lifespan and/or improve health of a mammal. Also provided are methods of treating, delaying, preventing or reversing progeria or related syndromes in a mammal using isolated autologous or allogeneic stem/progenitor cells and/or regulatory factors secreted or released therefrom. | 2013-12-19 |
20130336936 | CELL TRANSPLANTATION - The present invention provides polymers for use in preventing damage to the membranes of cells in fat grafts. Mixing of a triblock copolymer such as poloxymer P188 with adipocytes or adipose tissue to be transplanted into a subject is thought to stabilize the membranes of the cells leading to more successful fat transplantation in soft tissue reconstruction or augmentation. Such methods may also be used in the transplantation of adult stem cells or other cells derived from fat tissue. Other agents such as lipoic acid may also be added to the polymer/cell compositions for cell transplantation. | 2013-12-19 |
20130336937 | CHONDROGENIC DIFFERENTIATION MEDIA AND METHODS FOR INDUCING CHONDROGENIC DIFFERENTIATION OF CELLS - The invention provides chondrogenic differentiation media comprising chondrogenic growth factors and low-molecular-weight sulfated polysaccharide derivatives of marine native exopolysaccharides (EPS) excreted by mesophilic marine bacteria from deep-sea hydrothermal environments. The invention relates to methods for inducing chondrogenic differentiation in pluripotent or multipotent cells, to cartilage tissues obtained by such methods, and to the use of such cartilage tissues for therapeutic purposes. | 2013-12-19 |
20130336938 | TRANSPLANTATION OF CELLS INTO THE NASAL CAVITY AND THE SUBARACHNOID CRANIAL SPACE - A method of transplanting cells into a subject is disclosed. The method comprises transplanting the cells into the paranasal sinus of the subject or the subarachnoid cavity situated between the frontal bone of skull and the olfactory bulb of the subject. Devices for paranasal sinus transplantation and subarachnoid cavity transplantation are also disclosed. | 2013-12-19 |
20130336939 | ANTINEMATODAL METHODS AND COMPOSITIONS - There are provided methods and compositions useful in cell-cell fusion using Fusion Family (FF) proteins of nematode origin. There are further provided antinematodal methods and compositions, utilizing fusogenic proteins of the nematode Fusion Family. | 2013-12-19 |
20130336940 | MODIFIED PIG ISLETS FOR DIABETES TREATMENT - The present invention relates to a modified pig islet capable of producing higher levels of glucagon than a native pig islet or capable of producing a glucagon analog, and methods for obtaining thereof. The invention also relates to a method for treating Diabetes Mellitus, and/or for regulating blood glucose levels in a subject in need thereof, comprising the administration of the modified pig islets of the invention. | 2013-12-19 |
20130336941 | LONG LASTING ABSORPTION OF FLAVONOIDS - The present invention relates to methods for a ong-term and sustained release of flavonoids, in particular rhamnose-containing flavonoids, and for prolonging the uptake of said flavonoids in the gastro-intestinal tract. It further relates to compositions comprising said flavonoid and α-rhamnosidase. It also encompasses compositions comprising hesperidin and hesperetin-7-gluoside. | 2013-12-19 |
20130336942 | USE OF A PROBIOTIC TO REGULATE BODY WEIGHT - The use of probiotic bacteria that modulate expression of a number of satiety markers in the intestine and reduces fat deposition to promote an optimal body weight of a mammal is described. The invention further relates to a composition comprising such a probiotic strain of bacteria and/or a fraction of said strain and/or metabolite of said strain for the preparation of a composition for administration to a mammal for promoting an optimal body weight of a mammal. | 2013-12-19 |
20130336943 | MEANS AND METHODS FOR ACTIVATING VAGUS NERVE - An object of the present invention is to provide an effective means and method for activating vagal afferent nerve. The present invention provides a vagus nerve activator comprising bacterial cells and/or a treated product of a lactic acid bacteria as active ingredient(s). | 2013-12-19 |
20130336944 | Lactococcus Lactis Strains for Use in Improving Digestive Condition - The present invention concerns strains of | 2013-12-19 |
20130336945 | STABLE COMPOSITIONS OF TETRAHYDROBIOPTERIN - The present invention relates to stable pharmaceutical compositions of tetrahydrobiopterin and processes for producing such compositions. Particularly the present invention relates to stable pharmaceutical compositions comprising tetrahydrobiopterin and at least one stabilizing agent. | 2013-12-19 |
20130336946 | FUSION PROTEINS AND METHODS FOR TREATING HIV INFECTION AND AIDS RELATED SYMPTOMS - The present invention discloses pharmaceutical compositions and methods for using a fusion protein comprising a superoxide dismutase and a transit peptide. The present invention also discloses pharmaceutical compositions and methods for using the fusion protein in combination with other antiretroviral agents for treating patients with AIDS or HTV infection. | 2013-12-19 |
20130336947 | PEPTIDES AND USES - Disclosed herein are zinc finger peptides having at least 4 zinc finger domains, such as 6, 11, 12 or 18 zinc finger domains. The zinc finger peptides may be fused to effector domains for modulating gene expression. Zinc finger peptides of the invention are useful for targeting trinucleotide-repeat sequences in mutant genes and may have applications in gene therapy. The zinc finger peptides may have nucleic acid recognition sequences according to SEQ ID NO: 101. Also disclosed are methods for constructing poly-zinc finger peptides having arrays of at least 8 zinc finger domains, along with zinc finger frameworks that may be useful for selecting zinc finger peptides from libraries. | 2013-12-19 |
20130336948 | COSMETIC - A composition is provided that includes a fish spawn protein isolate. A natural product extract is also present that includes unsaturated fatty acids and sterols. An emulsifier is provided to form a mixture of the isolate and the extract. A composition is also provided that includes an egg hatching protein isolate and at least one biocide protective of isolate activity. An emulsifier forms a mixture with the isolate that has an aqueous phase buffered to a pH of between 5.6 and 7.9. A process of producing such a cosmetic has an emulsion or an aqueous phase that is buffered to a pH of between 5.5 and 7.9 prior to the addition of isolate to the emulsion. A process of improving skin appearance is provided that includes the application of the cosmetic to the skin at least three times per week to achieve the improvement of the skin appearance. | 2013-12-19 |
20130336949 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID - Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and | 2013-12-19 |
20130336950 | MATERIAL COMBINATION FOR TREATING INFLAMMATORY OR INFECTIOUS DISEASES - A material combination is configured to treat or prevent inflammatory and infectious diseases caused by fastidious anaerobic or facultative anaerobic microorganisms, such as bacteria or | 2013-12-19 |
20130336951 | COMPOSITIONS AND METHODS FOR MODULATING AMPA RECEPTOR-MEDIATED EXCITOTOXICITY - The present invention provides AMPAR excitotoxicity mediating polypeptides comprising the GAPDH(2-2-1-1) (I221-E250)amino acid sequence (SEQ ID NO:2). Also disclosed are nucleotide sequences encoding the polypeptides, methods of inhibiting GAPDH association with the GluR2 subunit or p53. Methods of inhibiting AMPA receptor mediated excitotoxicity using the polypeptides and nucleic acids are also disclosed. | 2013-12-19 |
20130336952 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS - The present disclosure relates to compositions and methods for accelerating the healing process of wounds, increasing the closure of skin wounds, and decreasing inflammation at the site of a skin wound. Specifically, the disclosure relates to compositions comprising a delta-PKC activator, an alpha-PKC inhibitor, and a pharmaceutically acceptable carrier that is free of Ca | 2013-12-19 |
20130336953 | USE OF CREATINE KINASE FOR PREVENTING OR TREATING ADDICTION TO OPIATES - The present invention relates to creatine kinase for use as a medicinal product or in the prevention or treatment of addictions or of addictive disorders associated with opiates, and to various other analytical uses or for filtration of creatine kinase. | 2013-12-19 |
20130336954 | Staphylococcal Phage2638A Endolysin Amidase Domain Is Lytic for Staphylococcus aureus - is notorious for developing resistance to virtually all antibiotics to which it is exposed. Staphylococcal phage 2638A endolysin is a peptidoglycan hydrolase that is lytic for | 2013-12-19 |
20130336955 | ANTIMICROBIAL FUSION COMPOUNDS AND USES THEREOF - A fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, polypeptide B; and at least one polypeptide A capable of viral entry inhibition; and/or at least one Cationic AntiMicrobial Peptide, polypeptide C. | 2013-12-19 |
20130336956 | RECOMBINANT ELASTASE PROTEINS AND METHODS OF MANUFACTURING AND USE THEREOF - The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention. | 2013-12-19 |
20130336957 | NOVEL PURIFICATION OF HUMAN, HUMANIZED, OR CHIMERIC ANTIBODIES USING PROTEIN A AFFINITY CHROMATOGRAPHY - Disclosed herein are compositions and methods for the isolation and purification of antibodies from a sample matrix. In particular, the present invention relates to compositions and methods for isolating and purifying antibodies exhibiting low or high binding capacity for Protein A resin. In certain embodiments, the methods herein employ a kosmotropic salt solution, an affinity chromatographic step, and may include one or more additional chromatography and/or filtration steps to achieve the desired degree of purification. The present invention is also directed toward pharmaceutical compositions comprising one or more antibodies purified by a method described herein. | 2013-12-19 |
20130336958 | NOTCH Inhibition In The Treatment Of Cardiovascular Disease - The present invention is directed to methods of treating or preventing atherosclerosis and other cardiovascular diseases by administering agents that inhibit or modulate the NOTCH signaling pathway. In addition, the invention encompasses methods for assaying compounds for their ability to treat atherosclerosis based upon their effects on NOTCH signaling, and for measuring levels of amount, function, or activity of NOTCH pathway components in biological samples. | 2013-12-19 |
20130336959 | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy - The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods. | 2013-12-19 |
20130336960 | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy - The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods. | 2013-12-19 |
20130336961 | B Cell Depletion for Central Nervous System Injuries and Methods and Uses Thereof - Therapeutic B lymphocyte (B cell) depleting antibodies and methods and uses thereof in the treatment of patients having central nervous system injuries are described. | 2013-12-19 |
20130336962 | AZIRIDINE BISPHENOL ETHERS AND RELATED COMPOUNDS AND METHODS FOR THEIR USE - Compounds having a structure of Formula I: | 2013-12-19 |
20130336963 | ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY - The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen. | 2013-12-19 |
20130336964 | ANTI-TRKA ANTIBODIES, DERIVATIVES AND USES THEREOF - The present invention relates to an antibody, recombinant or synthetic antigen-binding fragments thereof able to recognise and bind an epitope comprised in the TrkA amino acid sequence, medical uses thereof and a pharmaceutical composition comprising at least one of the above antibody, recombinant or synthetic antigen-binding fragments thereof. | 2013-12-19 |
20130336965 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS - The present invention provides a compound of formula (A): | 2013-12-19 |
20130336966 | CORONIN 1 MODULATORS FOR THE TREATMENT OF AUTOIMMUNE AND LYMPHOPROLIFERATIVE DISORDERS AND MYCOBACTERIAL INFECTIONS - The invention relates to the treatment of mycobacterial infections, autoimmune disorders, lymphoproliferative disorders and induction of immunosuppression following transplantation using coronin 1 and modulators of coronin 1. Particular modulators of coronin 1 are compounds which inhibit the production of coronin 1 or the formation of active coronin 1 from a coronin 1 precursor, partly or entirely inactivate coronin 1, inhibit concentration of coronin 1 at the site of T cell activation, or inhibit the coronin 1 mediated signaling pathway downstream of the T cell receptor. Examples of such modulators are antibody or antibody fragments, coronin 1 peptide fragments or corresponding phosphopeptides, or anti-sense oligonucleotides, e.g. siRNA or shRNA. The invention further relates to a method of screening for a compound effective in the treatment of mycobacterial infections, autoimmune disorders, lymphoproliferative disorders and induction of immunosuppression following transplantation comprising contacting a candidate compound with coronin 1 or coronin 1 expressing cells, and selecting appropriate compounds. | 2013-12-19 |
20130336967 | ANTI-BST2 ANTIBODY - BST2 antibodies were selected by using as an indicator the binding between BST2 antibodies and various splicing variants of human BST2 antigen. As a result, the present inventors successfully obtained BST2 antibodies that specifically recognize BST2D, which has been reported to be expressed at high levels in cancer cells. The antibodies of the present invention specifically bind to cells expressing BST2D. Non-specific antibody binding to non-target tissues, which results in the decrease of antibody concentration in blood, can be prevented by using the antibodies of the present invention therapeutically. Alternatively, the present invention provides diagnostic agents comprising an antibody of the present invention, which specifically detect tissues expressing BST2D. | 2013-12-19 |
20130336968 | PHARMACEUTICAL FORMULATION COMPRISING A BIOPHARMACEUTICAL DRUG - The present invention is related to a pharmaceutical formulation comprising a biopharmaceutical drug, said composition further comprising at least one mono- or dicarboxylic acid with a backbone of 2-6 C-Atoms, or at least one salt thereof. | 2013-12-19 |
20130336969 | USE OF OLFACTOMEDIN-4 PROTEIN (OLFM4) IN COLORECTAL CANCER DIAGNOSIS - The present invention provides a method for diagnosing KRAS mutations in colorectal cancers by measuring the level of OLFM4. In another aspect, the present invention relates a method of predicting the responds to a chemotherapeutic agent of a subject suffering from a colorectal cancer: according to the present invention, the by determining the OLFM4 levels. According to the present invention, the response can be predicted by determining the OLFM4 levels. This result in turn permits the design or the adaptation of a treatment of the said subject with the said chemotherapeutic agent. | 2013-12-19 |
20130336970 | Compositions and Methods for Treating and Diagnosing Cancer - The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cells. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells. | 2013-12-19 |
20130336971 | HOMODIMERIC PROTEIN CONSTRUCTS - The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins. | 2013-12-19 |
20130336972 | RECOMBINANT FC-FUSION PROTEIN OF THE FIFTH FIBRONECTIN TYPE III DOMAIN OF DCC - The present invention relates to DCC-fusion proteins, nucleic acid molecules encoding the DCC-fusion proteins, as well as methods for their production and their use in treatment of cancer such as colorectal cancer, NSCLC and metastatic breast cancer. The present invention also relates to methods of treating cancer such as colorectal cancer, NSCLC and metastatic breast cancer by administering DCC-fusion proteins. | 2013-12-19 |
20130336973 | Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain - Provided herein are isolated heteromultimers comprising: at least one single domain antigen-binding construct attached to at least one monomer of a heterodimer Fc region; wherein the heterodimer Fc region comprises a variant CH3 domain comprising amino acid mutations that promote the formation of said heterodimer with stability comparable to that of a native Fc homodimer; and wherein said isolated heteromultimer is devoid of immunoglobulin light chains and optionally devoid of immunoglobulin CH1 region. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics. | 2013-12-19 |
20130336974 | METHOD FOR DELIVERING AGENTS INTO CELLS USING BACTERIAL TOXINS - The invention provides compositions and methods for delivering a bioactive moiety comprising at least one non-natural component into a cell cytosol of an eukaryotic cell. The bioactive moiety is linked to an A component of a bacterial toxin, a functional wild-type or modified fragment thereof, or an A component surrogate or mimetic. For delivery, the cell is contacted with the linked bioactive moiety and a corresponding B component of the bacterial toxin or a functional fragment thereof. | 2013-12-19 |
20130336975 | ANTI-NGF COMPOSITIONS AND USE THEREOF - The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 2013-12-19 |
20130336976 | HUMAN IMMUNE THERAPIES USING A CD27 AGONIST ALONE OR IN COMBINATION WITH OTHER IMMUNE MODULATORS - Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited. | 2013-12-19 |
20130336977 | SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION - Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition. | 2013-12-19 |
20130336978 | Binding members for interleukin-4 receptor alpha (IL-4Ra) - 173 - Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4Rα), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4Rα, IL-4 and/or IL-13, examples of which are asthma and COPD. | 2013-12-19 |
20130336979 | DIAGNOSTIC AND TREATMENT OF CHRONIC HEART FAILURE - The invention relates to Apolipoprotein O (Apo O) as a biomarker for chronic heart failure. Moreover, the invention relates to a compound which may be an inhibitor of Apo O activity or an inhibitor of the Apo O gene expression for use in the treatment of chronic heart failure. | 2013-12-19 |
20130336980 | ST2L Antagonists and Methods of Use - The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing. | 2013-12-19 |
20130336981 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES - The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided. | 2013-12-19 |
20130336982 | ANTAGONIST ANTIBODIES AGAINST GDF-8 AND USES THEREFOR - The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies. Also provided are methods of using compositions comprising such antibodies to increase muscle mass or strength, and to treat or prevent muscular disorders, neuromuscular disorders, metabolic disorders, adipose tissue disorders or bone disorders. | 2013-12-19 |
20130336983 | PROGNOSIS AND TREATMENT OF BREAST CANCER - The present invention relates to an antibody which specifically binds a Spot 14 (S14 or THRSP) protein in human breast cancer cells and a method for using the same to predict disease-free survival and select treatment modalities for breast cancer. The present invention is also a method for inducing apoptosis in breast cancer cells by inhibiting the expression or activity of Spot 14. Compositions and methods for treating breast cancer are also provided. | 2013-12-19 |
20130336984 | ANTAGONISTIC DR3 LIGANDS - The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases. | 2013-12-19 |
20130336985 | MEDICAMENT AND A METHOD FOR REGULATION OF THE VASCULAR TONE - The method of treatment for diseases accompanied by disturbances of the vascular tone utilizes the use of ultra low doses of antibodies to a protein or a peptide involved in the vascular tone regulation or mediating the effects of other regulators; these antibodies are used in activated form produced by multiple subsequent dilution and external impact. | 2013-12-19 |
20130336986 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY - The present invention is related to compound capable of modulating the activity and/or expression of the protein kinases SCYL1, ADCK1, and GRK5, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of diseases of the carbohydrate metabolism. The invention is further related to methods of treatment of diseases of the carbohydrate metabolism, particularly diabetes mellitus type 2. | 2013-12-19 |
20130336987 | Identification of Therapeutic Targets in Cutaneous SCC - The present invention discloses a series of genes and/or proteins associated with cutaneous squamous cell carcinoma (cSCC) and provides polynucleotides and/or polypeptides for use in the treatment and/or prevention of cSCC. The invention further relates to methods of diagnosing cSCC and provides oligonucleotides/polypeptide probes and primers. | 2013-12-19 |
20130336988 | METHODS FOR TREATING EARLY STAGE OR MILD NEUROLOGICAL DISORDERS - This disclosure relates to modulation of the interactions between proNTs and p75 | 2013-12-19 |
20130336989 | METHODS OF IDENTIFYING A PATIENT POPULATION - Provided herein is a method for identifying a patient as a candidate for treatment with an aggrecanase inhibitor. Also provided is a method of evaluating the effectiveness of an aggrecanase inhibitor. | 2013-12-19 |
20130336990 | ENHANCEMENT OF THE ACTION OF ANTI-INFECTIVE AGENTS AND OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM AGENTS AND TRANSPORTATION OF NUCLEIC ACID SUBSTANCES - The invention provides a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the anti-infective agents, the group comprising of the antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, and from the group consisting of the CPNS agents selected from the group of compounds acting on the central or peripheral nervous system, but excluding coal tar solution and H1-antagonist antihistamines and also excluding anti-inflammatory, analgesic and antipyretic agents and also provides an enhanced method for the administration of a nucleic acid substance to the cells of an animal, a plant or a micro-organism. The method is characterised in that the agent or nucleic acid substance is formulated with an administration medium which comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which administration medium includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20:5ω3], decosahexaenoic acid [C22:6ω3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide. The formulations of such agents or substances form part of the invention | 2013-12-19 |